|
At the request of the U.S. Congress, the Institute of Medicine (IOM) is evaluating the implementation of the President's Emergency Plan for AIDS Relief (PEPFAR). PEPFAR was authorized under the United States Leadership Against HIV/AIDS, Tuberculosis, and Malaria Act of 2003 (Public Law 108-25), which authorizes more than $15 billion over five years for bilateral and multilateral programs to prevent HIV/AIDS, malaria, and tuberculosis infections and to treat and care for people infected with and affected by these diseases.
PEPFAR is focused in 15 countries with high prevalence rates of HIV/AIDS: Botswana, Cote d'Ivoire, Ethiopia, Guyana, Haiti, Kenya, Mozambique, Namibia, Nigeria, Rwanda, South Africa, Tanzania, Uganda, Vietnam and Zambia. In these focus countries, PEPFAR’s goals are to prevent 7 million new HIV infections, support treatment for 2 million people infected with HIV/AIDS, and support care for 10 million people infected and affected by HIV/AIDS, including orphans and vulnerable children.
The task of the IOM committee is to examine a variety of measures of program success that can be ascertained at different points across the implementation timeline. The committee is assisted in its work by three coordinated subcommittees focused on prevention, treatment, and care. The core committee is composed of 13 members, most of whom also serve on one of the subcommittees. The three subcommittees have 6 or 7 members each. The function of the subcommittees is to advise the core committee. All reports for this project will be authored by the core committee.
Three reports are planned : (1)Interim Letter Report released October 31, 2005 2)Consensus Report released March 30, 2007, and (3)Workshop held on April 30 and May 1 2007 and Workshop Summary published in Summer 2007.
You can provide feedback to the committee members and staff concerning this project through the National Academies Current Project System.
Please note that any comments that you submit to the committee through this website or otherwise, including your name and identifying information, will not be kept confidential and will be included in a Public Access File. The National Academies shall be authorized to use any such comments or submissions in accordance with the National Academies' Terms of Use Statement.
|